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Abstract
Background: The incapacity of articular cartilage (AC) for self-repair after damage ultimately leads to the development
of osteoarthritis. Stem cell-based therapy has been proposed for the treatment of osteoarthritis (OA) and induced
pluripotent stem cells (iPSCs) are becoming a promising stem cell source.
Results: Three steps were developed to differentiate human iPSCs into chondrocytes which were transplanted
into rat OA models induced by monosodium iodoacetate (MIA). After 6 days embryonic body (EB) formation
and 2 weeks differentiation, the gene and protein expression of Col2A1, GAG and Sox9 has significantly
increased compare to undifferentiated hiPSCs. After 15 weeks transplantation, no immune responses were
observed, micro-CT showed gradual engraftment and the improvement of subchondrol plate integrity, and
histological examinations demonstrated articular cartilage matrix production.
Conclusions: hiPSC could be an efficient and clinically translatable approach for cartilage tissue regeneration
in OA cartilages.
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Background
The increasing prevalence of degenerative cartilage
diseases, particularly osteoarthritis (OA), presents an
important social and healthcare problem. OA could
become the fourth leading cause of disability by the year
2020 [1]. OA is mediated by several pathogenic mecha-
nisms, including enzymatic degradation of extracellular
matrix, deficient new matrix formation, cell death, and
abnormal activation and hypertrophic differentiation of
cartilage cells [2]. The traditional therapeutic options for
OA are pharmaceutical interventions and joint replace-
ment surgery [3]. Methods for regenerating chondro-
cytes and cartilage tissue are expected to substitute or
supplement conventional therapies for such diseases. In
this respect, the use of stem cells in combination with
growth factors and scaffolds are highly considered as an
ideal option for articular cartilage (AC) regeneration [4].
To date, AC regeneration and cartilaginous tissue
engineering research has focused largely on the use of
autologous chondrocytes and mesenchymal stem cells
(MSCs) as cell resources. However, for autologous chon-
drocyte, donor site morbidity is a challenge [5]. Bone
marrow MSCs (BMSCs) possess limited proliferation
capability and decreased differentiation potential with
increasing donor age [6]. Moreover, the invasive proced-
ure required to harvest BMSCs presents another hurdle
to widespread clinical application. Adipose derived stem
cells are more easily harvested, but its differentiation
potency is not as strong as embryonic stem cells. Gener-
ation of induced pluripotent stem cell (iPSC) offers an
alternative cell source for regenerative medicine. Treat-
ments of neural and cardiovascular disease models
with iPS cell transplantation have already been re-
ported [7–9]. Compared to other fields, the research
for AC regeneration using iPS cells has just begun.
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Human iPSCs (hiPSC) established from autogenous
cells exhibit proliferation capability and pluripotency
similar to those of human embryonic stem cells (hESCs),
but no immune rejection and ethical problems. More-
over, to reduce the risk of tumorigenicity, new methods
for generating iPSCs without viral vectors have been
developed [10, 11]. Therefore, hiPSCs are viewed as a
promising new tool for regenerative medicine. hiPSCs
have been reported to generate cartilaginous tissue in
teratoma in vivo [12, 13], but limited data exists at
present regarding the in vitro chondrogenic differenti-
ation of hiPSCs. A reproducible method for in vitro
chondrogenic differentiation of hiPSCs hasn’t been
established. Teramura et al. reported mouse iPSC-
derived embryonic body (iPS-EB) derived cells expressed
surface markers similar to MSCs, these cells could dif-
ferentiate toward cartilage using TGF -β3 and BMP-2
[14]. Treatment of EBs with all trans-retinoic acid
followed by TGF -β3 and BMP-2 could also induce
chondrogenesis [15]. In terms of disease-specific iPS
cells, human OA chondrocyte-derived iPS cells have
been established and showed chondrogenic potential
using EB formation or co-culture with chondrocytes
[1, 16]. Koyama used a multistep culture method to
differentiate hiPSCs into chondrocytes, about 70 %
hiPSCs expressed type II collagen and aggrecan [17].
All these studies suggested that iPSC may be a poten-
tial alternative cell source for articular cartilage regen-
eration. The major drawback in the use of iPSCs for
tissue engineering is the difficulty in obtaining a
uniform interest cell population, which creates the
danger of teratoma formation from undifferentiated cells
[18]. Another drawback is the very low yield of the cells,
together with the fact that they do not emerge in culture
until 3 weeks after transduction [19]. All these caused the
application obstacle of iPSC in tissue engineering.
In this study, we have successfully differentiated iPS
cells into chondrocytes in vitro in a simple way with a
high differentiation ratio, after transplantation of iPS
derived chondrocytes into MIA induced OA model, we
can see the repairation of knee lesion, and therapeutic
effects can be observed from the improvement of knee
function.
Methods
Cell culture and differentiation
The study was approved by Medical Ethical Committee
and Animal Ethical and Welfare Committee of Shenzhen
University. All patients provided written informed consent.
hiPSC was generated by introducing four reprogram-
ming factors (Oct3/4, Sox2, Klf4, and c-Myc) into
dermal fibroblasts from the OA woman (51 years old,
Kellgren & Lawrence scoring III), and characterized by
Peking Cellapy Biotechnological company. Three of the
identified iPS clone were used in this study and hiPSCs
were maintained with PSCeasy medium (Cellapy Bio,
China), hiPSCs after passage 20 from three clones were
used for the differentiation experiments. iPSC from one
of the clones were used for transplantation. For EB for-
mation, hiPSC colonies were harvested by treating with
0.5 mg/mL Dispase, and then plated onto suspension
culture dishes, where they were allowed to aggregate in
a maintenance medium (DMEM/F12 supplemented with
10 % FBS, 100U/mL penicillin, and 100 μg/mL strepto-
mycin). After 5 days as a suspension culture, EB media
were changed for chondrogenic media (DMEM/F12 sup-
plemented with 10 % FBS, 1%ITS, 50 μg/mL ascorbic acid
2-phosphate, 100 mg/mL sodium pyruvate, 40 μg/mL L-
proline, 100nM dexamethasone, 10 ng/mL transforming
growth factor-β1 (TGF- β1), 100U/mL penicillin, and
100 μg/mL streptomycin) and cultivated for another
2 days. Then five EBs were transferred to gelatin coated
dish with chondrogenic media, after 1 and 2 weeks differ-
entiation, cells sprouted from EBs were examined, and the
cells which differentiated for 2 weeks were harvested for
cell transplantation. EBs cultivated in DMEM which con-
tained only 10 % FBS, 100 U/ml penicillin, and 100 μg/ml
streptomycin used as control. All materials in the media
are purchased from Invitrogen.
Histological analysis and immunofluorescence assay
After cells were sprouted from EB and differentiated for
1 or 2 weeks, we fixed differentiated cells and undiffer-
entiated iPSCs in 4 % paraformaldehyde (pH 7.4, Sigma-
Aldrich) at room temperature, and stained with toluidine
blue. For the immunofluorescence assay, undifferenti-
ated iPSCs and their differentiated derivatives were fixed
in cold acetone for 30 min at 4 °C, then cells were rinsed
with PBS three times and blocked in 10 % normal goat
serum for 20 min. Samples were incubated with primary
antibodies (Anti-CollagenII, Abcom) overnight at 4 °C,
then rinsed with PBS three times and incubated with
Alexa Fluor 594 Donkey-conjugated secondary anti-
bodies (Invitrogen) for 2 h at room temperature. Cells
were rinsed with PBS and mounted in aqueous mount-
ing medium containing the nuclear counterstain DAPI
(4,6 diamidino-2-phenylindole; Sigma-Aldrich). Images
were captured using an IX-71 fluorescence microscope
(Olympus, Japan).
Real-time reverse transcription–polymerase chain reaction
Total RNA was extracted from cell pellets (5 × 105cells/
group) with Trizol (Qiagen). To ensure the complete re-
moval of DNA, we included a 15-min DNase I (Qiagen)
treatment before the washing step. First-strand cDNA
synthesis was performed using PrimeScript™ RT reagent
Kit with gDNA Eraser (TaKaRa) with random hexamers.
Real-time reverse transcription–polymerase chain reaction
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(RT-PCR) was performed with SYBR Premix Ex Taq™ II
(Tli RNaseH Plus) (TaKaRa). Complementary DNA was
mixed with TaqMan Universal PCR Master Mix (Applied
BioSystems) and TaqMan Gene Expression Assay (Applied
BioSystems). All RNA samples were titrated to yield equal
amplification of β-actin as an internal normalization con-
trol, and the expression level of each mRNA was calculated
using the 2-ΔΔCT method. Reactions for each sample were
performed in triplicate. After an initial denaturation step
(95 °C for 30s), amplification was performed for 40 cycles
(5 s denaturation at 95 °C and 30s extension at 60 °C).
Table 1 showed the primer sequences we used in PCR.
OA induction and cell transplantation
Sprague Dawley rats (weight 200–230 g) were housed
under standard laboratory conditions (in a temperature
controlled (21 ± 1 °C) room with a normal 12-h light/
dark cycle). Animals retained full mobility and continued
to grow normally. For induction of MIA-induced arth-
ritis, rats were anesthetized with 2 % Pentobarbital
Sodium and given a percutaneous single intra-articular
injection of 0.5 mg of monosodium iodoacetate (MIA;
Sigma) in right knee, or saline vehicle through left knee
(N = 3). MIA was dissolved in physiologic saline and
administered in a volume of 25 μl using a 26-gauge, 0.5-
inch needle. The left contra-lateral knee was used as a
behavioral and histological control. The hind limbs of all
the rats were imaged with high resolution in vivo micro-
CT at 1 and 5 weeks post-MIA injection. After 1 week
MIA injection, iPSCs and differentiated iPSCs were
collected, adjusted cell density as 1 × 106cells/ml, then
500 μl cell suspension were injected into right knee.
After 15 weeks transplantation, all the knees were
imaged with micro-CT and examined by sections. Total
13 SD rats were used in this study, three for control
and MIA injection, 10 for MIA injection and cell
transplantation (five for iPS cells and five for iPS-derived
chondrocytes, right knee for MIA injection, left knee for
cell transplantation after MIA injection, total knee sample
for each group is 10). The animal handling and experimen-
tal procedures outlined in this study were carried out in
accordance with Animal Ethical and Welfare Committee
of Shenzhen University and The Institute of Medical and
Veterinary Science Animal Ethics Committee.
In vivo micro-computed tomography (micro-CT) imaging
In vivo micro-CT imaging was performed using a
bench-top cone-beam type in vivo animal scanner
(Skyscan model 1076, Skyscan, Kontich, Belgium). Each
rat was anesthetized with Pentobarbital Sodium and
placed in the scanner bed in a supine position. The
MIA-injected knees and the contralateral control knees
were scanned separately. During each scan only the knee
for image data acquisition was irradiated, while the
contralateral limb and the rest of the body were lead
shielded from radiation. The hind limb of the rat was se-
cured into a customized leg fixative device consisting of
a cylindrical plastic holder fitted to a polystyrene tube.
This allowed positioning of the hind limb close to the
central scanner axis, preventing any movement of the
limb during scanning. The total scan time for each limb
was 20 min during which the rat was under anesthesia.
The scans were performed using the following scanner
settings: X-ray source voltage 60 kVp, current 100 μA, a
1-mm thick aluminum filter to reduce beam-hardening
artefact, one frame averaging. The pixel size was 9 μm,
the exposure time was 1.1 s, and the rotation step was
0.8°, with a complete rotation over 180°. The cross-
sectional images were reconstructed using a filtered
back-projection algorithm (NRecon, V 1.4.4, Skyscan,
Kontich, Belgium). For each scan, a stack of 1800 cross-
sections was reconstructed, centered over the knee-joint
(total reconstructed height about 16 mm), with an inter-
slice distance of one pixel (9 μm). The reconstructed
images were of 1500 × 1500 pixels each, 9 μm pixel size,
and were stored as 8-bit images (256 grey levels).
Histological analysis
After imaging, the animals were sacrificed and the each
knee was dissected aseptically, and fixed in 4 % parafor-
malin, then decalcified in EDTA, which was changed
every 5 days. The decalcified knee was cut in the mid-
sagital plane, and paraffin-embedded. Serial knee sec-
tions of exact 5 μm thickness from the middle part of
the knee were obtained to prepare slides. Rat knee joints
were stained with hematoxylin and eosin (H&E) to
assess general morphology and neovascularization. For
immuno-histochemistry, Anti-CollagenIIprimary antibody
(Abcam) was used in 1:500 dilution. All samples from
both knees were stained, and examined independently by
Table 1 Primer sequences of sepecific genes
Primer name Sequence(5' to 3')
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two observers. Sections were stained for GAGs with 0.5 %
Safranin-O and 0.2 % Fast Green counterstain. For each
sample, three sagittal sections were used for thickness his-
tomorphometry analysis and digital images of each section
were captured.
Statistical analysis
Data are presented as mean ± standard deviation. The
comparisons among different groups were performed
using multiple–factorial analysis of variance (ANOVA).
When ANOVA testing indicated overall significance of
main effects and without interaction between them, the
difference between individual time points and sites was
assessed by post hoc tests. The level of significance was
set at P < 0.05. All data analyses were performed using
SPSS 15.0 analysis software (SPSS Inc).
Results
Morphological changes of hiPSCs during differentiation
We used a three step culture method combining spon-
taneous differentiation via EB formation, pre induction
in EB suspension culture, cell outgrowth from EBs on
culture dishes (Fig. 1). We first made undifferentiated
hiPSCs into EBs. hiPSCs contained in EBs retained pluri-
potency in vitro. Before proceeding to adhesive culture,
we included a pre induction with chondrogenic media in
EB suspension culture. After 2 days pre induction, EBs
were transferred to gelatin coated culture dish, cells were
sprouted from EB and differentiated in chondrogenic
media for another 1 or 2 weeks.
Before differentiation, hiPSCs in monolayer culture were
small and fibroblast-like,and grew as colon while cultured
on matrigel, we chose no differentiation colons with similar
size for EB formation. After 5 days suspension culture, we
replaced the EB media for chondrogenic media as pre
induction. During pre induction, EBs exhibited better
morphology and less internal necrosis. When EBs were
cultured in gelatin coated culture dish, some large spherical
cells with chondrocyte-like morphology sprout from EBs.
Immunohistochemical analysis of chondrogenic
differentiation markers
After 2 weeks induction, the entire EB with sprouted cells
were intensely stained with Toluidine blue (Fig. 2a), sug-
gesting maturation of cartilaginous extracellular matrix.
EBs cultivated in DMEM as control showed Toluidine
blue negative staining. To confirm the chondrogenic
differentiation capability of hiPSCs, we detected type II
collagen expression (Fig. 2a). Cells in differentiated EBs
exhibited strong positive staining for type II collagen. EBs
cultured with DMEM did not exhibit cell morphological
change or the expression of chondrogenic markers.
After confirming the expression of chondrogenic
differentiation marker by immunohistochemistry in both
differentiated and undifferentiated hiPSC, we next
examined the expression of chondrogenic markers at the
mRNA level (Fig. 2b). We analyzed both chondrogenic
differentiation markers and ES cell markers expression
by real-time RT-PCR after 7 and 14 days differentiation.
COL2A1, ACAN and SOX9 expression was also present
Fig. 1 Schematic diagram of the culture protocol for chondrogenic differentiation of hiPSCs. The differentiation culture protocol consists of 3
steps: (1) Embryoid body (EB) formation in suspension culture dishes; (2) Pre induction of EB in the chondrogenic induction medium; (3) Cell
outgrowth from EBs on gelatin-coated dishes in the chondrogenic induction medium. During differentiation, histological and gene expression
analyses were performed at days 7 and 14. Scale bar: 100 μm
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in undifferentiated EBs, however, after 2 weeks for differ-
entiation, the expression of COL2A1, ACAN and SOX9
was dramatically upregulated. Coordinarily, ES cell
markers, Oct4 and Nanog expression was decreased
significantly compare to undifferentiated EBs and iPSCs.
However, it seems the expressions of both kinds of
markers are similar between undifferentiated EBs and
the EBs differentiated for 14 days.
Bone histomorphometric changes and subchondral
trabecular bone
The microstructure of subchondrol bone change with
OA, to assess the change of bone mass and bone trabec-
ula, microCT was used to observe the changes of bone
mineral density (BMD), Tb.Th, Tb.N and Tb.Sp at 2, 5,
7, 10 and 15 weeks. There was a significant increase in
total BMD, Tb.Th and Tb.N in the tibial subchondral
bone of both the MIA injected knee and the control
knee over time (Fig. 3). This was due to the natural
growth of the animal. The total Tb.Sp of both the
control tibia and the tibia of the MIA-injected knee
were significantly decreased at 15 weeks compared to
2 weeks (Fig. 3).
The BMD and Tb.N were significantly lower in the
MIA-injected knee compared to the control knee in all
the three tibial compartments. In the 5 weeks after cell
injection, there was a slightly increase of BMD, at
7 weeks, the BMD was significantly low and maybe the
osteoporosis was appeared. However, the BMD was in-
creased quickly after 10 weeks, and it was even close to
the control knee, the possible reason is endochondral
ossification. At 5 weeks, the Tb.N was suddenly in-
creased significantly, bone trabecules were broken in
subchondral bone may cause the higher Tb.N. At
15 weeks, the Tb.N did not differ significantly between
the tibia of the cell-injected knee and control knee.
The Tb.Th and Tb.Sp were increased in the MIA-
injected knee compared to the control knee at all the
time points. After cell injection, the values of Tb.Th
were decreased and almost close to the control knee at
Fig. 2 Examination of chondrogenic markers after differentiation. After EBs were differentiated for 2 weeks, staining with Toluidine blue revealed
spherical cell morphology and interstitium, type II collagen was also detected after differentiation (a). The expression of chondrogenic differentiation
markers was also analyzed by real-time PCR (b). Gene expression is normalized to that of beta–actin. Differentiated hiPSCs in monolayer culture
exhibited high expression of COL2A1, ACAN and SOX9 compare with undifferentiated iPSCs. The expression was increased significantly at later
stages (day 14). *Significant change relative to control (n = 4). Data are shown as the mean ± SD
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7 weeks. In the 5 weeks of cell injection, although there
was a slightly decrease of Tb.Sp, it were increased
quickly in the following weeks. After 15 weeks, the
knee injected with hiPSC derived chondrocyte, the
values of BMD, Tb.Th, Tb.N and Tb.Sp were much
more close to the control knee, compared with the
knee injected with hiPSC.
Qualitative subchondral bone changes
All the rats showed pathological subchondral bone
changes in the MIA-injected knee, whereas the contra-
lateral control knee showed no OA-like changes in the
tibial subchondral bone microarchitecture throughout
the study duration (15 weeks). Morphologic evaluation
of the MIA-injected knee over time showed sclerosis in
the tibial subchondral bone at 15 weeks after MIA injec-
tion, particularly in the medial tibial condyle (Fig. 4).
The tibial subchondral plate of the MIA-injected knee
was breached in focal areas, these breaches were con-
firmed by histology. From the micro-CT images, empty
spaces were observed in the medial tibial subchondral
bone of the MIA-injected knee at 15 weeks. These
empty spaces were confirmed as cysts from the histology
sections. The porosity of the tibial subchondral plate
was significantly increased in the MIA-injected knee
compared to the control knee in all the three compart-
ments analyzed (P < 0.01). Three dimensional surface
rendering of the MIA-injected knee showed erosion and
pitting of the tibial subchondral plate, which was more
severe in the medial tibial plateau, whereas the control
knee maintained the subchondral plate integrity. After
one week MIA injection, we transplanted iPS cells or
iPS derived chondrocytes into articulation, at 15 weeks,
iPS cells and iPS derived chondrocytes transplanted
knee didn’t show any significant difference, however,
compared with MIA-injected knee, no obvious breaches
and empty spaces were observed in the tibial sub-
chondral bone, the porosity of the tibial subchondral
plate was slightly decreased compare with MIA-injected
knee (Fig. 4).
Macroscopy
All the rats developed cartilage lesions in the tibia of
MIA-injected knees. After 15 weeks cell injection, there
was no significant difference compared with MIA-
injected knees. The cartilage plates were easily peel off
from the joint, however, after MIA and cell injection, the
cartilage plates were sticked to the joint and hard to peel
off. The tibial cartilage of the MIA-injected and cell
injected knee all showed focal lesions with discoloration
indicating cartilage degradation (Fig. 5, black arrow).
This was more prominent in the central region of the
medial tibial plateau, whereas cartilage degradation
remained at a moderate stage on the lateral side. Macro-
scopically, the control tibia showed no cartilage lesions
in the medial and lateral tibial plateau (Fig. 5, red arrow).
Cartilages were repaired after the transplantation of iPSCs
and iPS derived chondrocytes. hiPS derived chondrocytes
seems have stronger repair ability than hiPSCs (Fig. 5,
white arrow).
Fig. 3 Plots of morphometric parameters of subchondral trabecular bone determined by micro-CT at 2, 5, 7, 10 and 15 weeks post-MIA injection. MIA-
injected rat almost couldn’t move after 10 weeks, and it’s too fat to do the CT examine, so no data can be get at 15 weeks in MIA group. Error bars = SD.
MIA, monosodium iodoacetate; BMD, Bone Mineral Density ; Tb.Th, trabecular thickness; Tb.N, trabecular number; Tb.Sp, trabecular separation
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Histology
The articular cartilage from control knee exhibited
typically four intact cell layers including a superficial,
transitional, deep radial, and deep calcified zone, and
uniformly-distributed proteoglycan as the main extra-
cellular matrix component (Fig. 6). However, all the
rats showed articular cartilage degradation in the tibia
of the MIA-injected knee. At 15 weeks, the subchon-
dral plate was breached in focal areas with cartilage
damage. The sections showed OA-like features such as
surface discontinuity, loss of proteoglycans, disorientation
of chondrocytes and subchondral bone sclerosis. After
Fig. 4 Micro-CT images of tibia at 15 weeks post injection. Three-dimensional surface rendering obtained from micro-CT images of a control knee
(Control), a MIA-injected knee (MIA), iPS cells transplanted knee (iPSC) and iPS derived chondrocytes transplanted knee (iPS-chondro) at 15 weeks
after injection. The control knee maintained the subchondral plate integrity with a smooth contour. The MIA-injected knee showed erosion and
pitting of the tibial subchondral plate, which was more severe in the medial tibial plateau. Micro-CT, micro-computed tomography; MIA, monosodium
iodoacetate; M, medial tibial plateau
Fig. 5 Macroscopic images of tibia at 15 weeks post injection. The control tibia had no cartilage lesions on the medial compartment and lateral
compartment of the tibial plateau (red arrow), whereas the MIA injected tibia had severe cartilage lesions on the medial tibial plateau (black arrow).
After cell transplantation, the repair was obviously observed in iPS derived chondrocytes transplanted knee (white arrow). MIA, monosodium
iodoacetate, all the arrow point to medial tibial plateau
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transplantation of iPS derived chondrocytes, cartilage
surface was continue, proteoglycan was increased compare
with MIA-injected knee, and appeared proliferating chon-
drocytes suggesting cartilage repair. While after iPS cells
transplantation, the repair was not so obvious (Fig. 6).
Immunostaining of the neo-cartilage for collagen II also
indicate the repair of iPS derived chondrocytes (Fig. 6).
The MIA cartilage showed the less collagen compare with
control cartilage, while after injection of iPSCs and iPS
derived chondrocytes, collagen II increased compare with
MIA cartilage, iPS derived chondrocytes injection can pro-
duce more collagen II compare with iPSCs injection,
which indicate that iPS derived chondrocytes have better
repair effect than iPSCs only. However, the amount of col-
lagen IIin cartilage after iPSCs injection still couldn’t reach
to that of control cartilage.
The images of tibial articular cartilage sections stained
with Safranin O-Fast green are shown in Fig. 6. The
MIA cartilage displayed extensive proteoglycan loss,
which was not observed in the saline injected
contralateral control. After tansplantation of iPSCs, it
showed localized degeneration with regional thickening
of the medial tibial plateau, oblique fissures within the
superficial bone were still exist, subchondral bone re-
sorption pit, remodeling and thickening subchondral
bone can be observed. However, the restore efficiency
was much better in iPS-chondrocyte group than the
iPSC group.
Discussion
Articular cartilage tissue is hard to regenerate after in-
jury because of the innate avascularity, low cellularity
and low cell turnover. Therefore, the development of
treatments allowing successful regeneration of cartilage
lesions to avoid further degeneration of focal articular
defects represents a major challenge [20]. Researchers
tried to find good methods to replace or repair diseased
or damaged cartilage tissue [21–23]. Cell regeneration
seems a good way to regenerate cartilage tissue, and it
has been driven by discovery of iPSCs. iPSCs can
Fig. 6 Histological analysis of knee sections. HE staining, Immunostaining of collagen II, Safranin O/Fast green staining were did to test the repairment
of iPSCs. MIA-injected knee (MIA) showed obvious cartilage damage compare with normal knee (Control), while transplantation of iPS cells or iPS
derived chondrocytes, the cartilage was repaired, and iPS derived chondrocytes (iPS-chondro) seems have stronger repair ability than iPS cells (iPSC)
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proliferate and differentiate into a variety of different lin-
eages, and it can be applied to personalized therapies,
which provide an intriguing alternative to the use of
stem cells in regenerative medicine [24, 25].
The differentiation efficiency of iPSC into chondrocyte
became the main obstacle in clinic use. There are two
methods which have been used to induce the differenti-
ation of stem cells into chondrocytes: application of
growth factors in medium and co-culture with chondro-
cytes. However, both culture with a conditioned medium
and co-culture with other cells lack reproducibility and
efficiency. Many attempts have been made to induce
chondrocytes from ESCs in vitro by pellet or micromass
culture with co culturing system [26, 27] or limb bud
progenitor cells from a developing embryo, culture with
a conditioned medium, genetic manipulation, and use of
biomaterials [28, 29]. In our study, we made EBs from
iPSCs, the high-density 3D microenvironment is thought
to facilitate cell–cell and cell–matrix interactions, and
therefore mesenchymal condensation occurs before
chondrogenic induction. After EB formation, we did
2 days pre induction to differentiate chondrocytes in 3D
microenvironment, which mimic in vivo limb develop-
ment. When differentiate chondrocytes in a two dimen-
sional (2D) EB direct-plating outgrowth system, cells
change their morphology, express chondrogenic differ-
entiation markers, and produce an extracellular matrix
that contains acidic proteoglycans, which stain positive
for Toluidine blue, the positive area and intensity of
Toluidine blue staining, which indicated the existence of
acidic proteoglycans. The chondrogenic transcription
factor Sox9 is required for precartilage condensation and
directly regulates the transcription of type II collagen
and aggrecan [30–32], Type II collagen is an early chon-
drogenic differentiation marker, and aggrecan is a major
sulfated proteoglycan of the cartilage matrix and a highly
specific marker of differentiated chondrocytes [32, 33].
From the genetic and protein expression studies, we can
see that Sox9, aggrecan and collagen II expression in-
creased significantly after differentiation, which indicate
the successful differentiation of iPSCs into chondrocytes.
Previous investigations, whatever coculture system or
conditional medium, expression level of chondrogenic
markers was low, and immunofluorescence did not
clearly reveal morphological characteristics of chondro-
cytes [34], a discrepancy between gene expression and
protein expression of type II collagen has been reported,
which means translation might be destabilized in the
culture conditions, and cells in pellets are still immature
chondrocytes, and do not produce enough collagen to
be detected by immunohistochemistry besides, it need
multiple steps and a long time to show the chondrocyte
specific markers [17]. In our differentiation system, we
developed an efficient, simple and reproducible system
to differentiate iPSCs into chondrocytes, the total process
from iPSC to chondrocyte is just 2 to 3 weeks. During
induction, all the cells spread out from EB can get enough
TGF for differentiation, besides, preinduction might also
improve maturation of chondrocytes in our method,
resulting in enhanced expression of type II collagen and
aggrecan protein.
To validate the repair capacity of human iPSCs for OA
knee, in vivo study was performed. Many investigators
have shown that intra-articular injection of MIA, which
is an inhibitor of glycolysis that disrupts metabolism in
chondrocytes, causes joint tissue damage that may
mimic clinical OA in patients [35–37] The MIA model
leads to global degenerative changes, which is a quick,
easy and reproducible OA model, and animals exhibit
signs of OA related pain. So in this study, we used the
MIA-induced OA rat model to pursue iPSC therapeutic
efficiency for OA knee. Using this verified animal model,
we examined the therapeutic effects of iPSCs and iPS
derived chondrocytes.
After iPS cell transplantation, we found some areas of
the articular cartilage were still intact, the thickness of
the subchondral plate became thinner compared with
MIA-injected knee, iPS derived chondrocytes trans-
planted articular cartilage have thicker subchondral bone
compare with that of iPSCs transplantation. The sub-
chondral bone and articular cartilage act as a functional
unit in the joint [38]. In human osteoarthritis joints, the
subchondral plates become significantly thicker relative to
that of healthy subjects [39, 40]. The subchondral bone
was modeled post surgery in MIA-induced OA models
and their thickness became thinner, which is similar with
the change of subchondral bone in human OA.
The obvious cartilage tissue formation generated from
iPSCs was observed from histological examination at
15 weeks. Because of low immunity, no immune re-
sponses were observed after iPSC transplantation. The
observation suggests that iPSCs and iPS derived chon-
drocytes have therapeutic effects, and partial differenti-
ated iPSCs may even have stronger therapeutic effects
than that of pure iPSCs. Compare with MIA cartilage,
there appeared more collagen and aggrecan, which indi-
cate that iPSC injection can differentiate more chondro-
cytes and produce more collagen and aggrecan to repair
damaged cartilage. Several studies also indicated that
combination of mesenchymal stem cells with chondro-
cytes had better therapeutic effects than mesenchymal
stem cells only [41]. The reason could be that partially
differentiated iPSCs have more chondrogenic potential
than undifferentiated iPSCs in vivo chondrogenic micro-
environment. The therapeutic effects were also identified
by the activity of rats. After OA injection, rats moved
slowly and became fat, and nearly cannot move at all at
10 weeks. However, after cell transplantation, rats were
Zhu et al. BMC Biotechnology  (2016) 16:78 Page 9 of 11
thinner and moved faster than OA rats, which indicate
the improved joint functionality and reduced lameness.
Even though we observed improved joint functionality
and reduced lameness after cell transplantation, but the
rats still have dyskinesia, and the joint didn’t recover
their function completely. The direct injection of stem
cells to the joint can boost the normality limited repair
and limit destructive processes, it may be only suitable
for the early-stage OA, further work is needed to focus
on stem cell based cartilage tissue engineering strategies
for end-stage OA.
Conclusions
In summary, we developed an efficient, simple and repro-
ducible system to differentiate iPSCs into chondrocytes
with a high differentiation ratio, the total process from
iPSC to chondrocyte is just 2 to 3 weeks. After transplant-
ation of iPS derived chondrocytes into MIA induced OA
model, the knee lesion was obviously repaired, and thera-
peutic effects can be observed from the improvement of
knee function. The changes in cartilage and subchondral
trabecular bone structure observed in the MIA rat model
before and after transplantation reveal the therapeutic
effects of iPS derived chondrocytes, at the same time,
micro-CT and histological examination showed that sub-
chondral trabecular bone structure didn’t recover com-
pletely, cartilage tissue engineering may be needed for the
serious OA therapy.
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